The Parachute® Implant System is a ventricular partitioning device developed by Cardiokinetix Inc. It is used to isolate damaged heart muscle in patients with symptoms of heart failure due to ischaemic heart disease.
After a heart attack, the damaged heart muscle can become over stretched as it has less resistance than undamaged muscle and is unable to contract. The left ventricle in the heart then enlarges as healthy muscle tries to compensate for lost function. This progressive enlargement eventually overloads the heart, causing a decrease in cardiac output and resulting in symptoms of heart failure such as fatigue, shortness of breath and fluid accumulation.
Icosapent ethyl is in clinical development as a treatment to reduce the risk of cardiovascular events in high-risk patients who have their cholesterol levels controlled with statin treatment, but have elevated triglycerides and other cardiovascular risk factors. Cardiovascular events include heart attack, angina and stroke. These diseases are the main cause of death in the UK, accounting for over a quarter of deaths each year. Patients receiving statin treatment are still at a high risk and would benefit from treatment to reduce cardiovascular events.